Aptorum Group (Aptorum Group) Common Stock : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Common Stock?

Aptorum Group's quarterly common stock increased from Jun. 2022 ($35.70 Mil) to Dec. 2022 ($35.71 Mil) but then declined from Dec. 2022 ($35.71 Mil) to Jun. 2023 ($0.00 Mil).

Aptorum Group's annual common stock increased from Dec. 2020 ($34.02 Mil) to Dec. 2021 ($35.64 Mil) and increased from Dec. 2021 ($35.64 Mil) to Dec. 2022 ($35.71 Mil).

Aptorum Group Common Stock Historical Data

The historical data trend for Aptorum Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Common Stock Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

28.98

29.04

34.02

35.64

35.71

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial							35.61	35.64	35.70	35.71	-

Aptorum Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.